{ "Tempol for Reducing Side Effects of Head and Neck Cancer Treatment", "This study is testing whether an oral solution called Tempol can help prevent or reduce common side effects from radiation and cisplatin chemotherapy for head and neck cancer. These side effects include mucositis (mouth sores), nephrotoxicity (kidney damage), and ototoxicity (hearing damage). You may be able to join if you are 18 or older, have squamous cell cancer of the head and neck, and are scheduled to receive radiation therapy. The study aims to enroll 120 participants and will monitor these side effects over 10 weeks to see if Tempol is effective. A placebo solution, which looks and tastes similar to Tempol but contains no active medicine, will also be used for comparison.", "design": "This interventional study plans to enroll 120 participants. It compares Tempol oral solution to a placebo solution.", "commitments": "Participants will be monitored and assessed for mucositis, nephrotoxicity, and ototoxicity over a 10-week period.", "compensation": "Not stated in the trial record.", "follow_up": "Participants will be monitored for 10 weeks, with mucositis measured at the end of this period.", }

Study design

Not specified.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.